Pfizer Settles $345M EpiPen Consumers Suit, But Viatris Marches On
After four years of litigation, Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan establish a monopoly for the EpiPen autoinjector device.
You may also be interested in...
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face if confirmed to a second stint as the nation's top medtech regulator.
US DoJ collected more than $1bn in penalties from device manufacturers this year, chiefly on false claims and manufacturing violations. Here is a roundup and sortable table of the payouts.
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.